PHAR, in collaboration with Novartis, published findings from a modified Delphi panel summarizing expert clinical consensus on how to classify and manage pharmacodynamic breakthrough hemolysis (BTH) in patients with paroxysmal nocturnal hemoglobinuria (PNH) treated with complement inhibitors. The paper presents the group’s agreed-upon recommendations on how to manage BTH caused by a complement-amplifying condition, as well as provides a severity classification system for BTH and strategies to mitigate risk of BTH in special circumstances (e.g., vaccination, planned or unplanned surgery, and pregnancy). In general, as severity of BTH increased, experts agreed more interventions to manage the BTH were appropriate. The full manuscript detailing the methods and findings are published in Hematology, or can be found on the PHAR Publications page.